Jonathan Biller

Chief Legal Officer at Agios Pharmaceuticals, Inc.

Jonathan Biller

Jonathan Biller

Chief Legal Officer at Agios Pharmaceuticals, Inc.

Overview
Career Highlights

Celgene Corp.
Bunge Ltd.

RelSci Relationships

2585

Birthday

1963

Age

57

Contact Data
Trying to get in touch with Jonathan Biller? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Jonathan Biller likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Delinia, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Agios Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Celgene Corp.

Relationship likelihood: Strong

President, Research & Early Development at Celgene Corp.

Relationship likelihood: Strong

President, Global Hematology & Oncology at Celgene Corp.

Relationship likelihood: Strong

Senior Vice President, Chief Compliance Officer at Celgene Corp.

Relationship likelihood: Strong

Executive Vice President & Chief Financial Officer at Bristol-Myers Squibb Company

Relationship likelihood: Strong

Executive Vice President, Head of Business Development & Global Alliances at Celgene Corp.

Relationship likelihood: Strong

President & Director at Celgene Corp.

Relationship likelihood: Strong

Chairman of the Board, Chief Executive Officer, Founder at Celularity, Inc.

Relationship likelihood: Strong

Paths to Jonathan Biller
Potential Connections via
Relationship Science
You
Jonathan Biller
Chief Legal Officer at Agios Pharmaceuticals, Inc.
Education
BA

Brown University is located in historic Providence, Rhode Island and was founded in 1764. It is the seventh-oldest college in the United States. Brown is an independent, coeducational Ivy League institution comprising undergraduate and graduate programs, plus the Alpert Medical School, School of Public Health, School of Engineering, and the School of Professional Studies.

JD

Located in New Haven, Connecticut, Yale Law School is one of the world’s premier law schools. It offers an unmatched environment of excellence and educational intimacy in the form of world renowned faculty, small classes, limitless opportunities for clinical training, and strong encouragement of public service. The Law School is small by design; its impact on the world is measured by its accomplished graduates and its ongoing scholarship and outreach through numerous centers and projects. For students, the experience is unparalleled. The faculty-student ratio supports a vast array of courses and opportunities for independent research and student-organized seminars. Students get practical training by representing real clients in clinics starting in their first year. Throughout, a spirit of collaboration reigns. All first-term courses are ungraded, and subsequent classes are graded honors/pass/low pass. Yale Law School is unique among law schools in that it produces leaders in all walks of life: distinguished deans and faculty members at law schools across the country and the world; industry CEOs and corporate counsels; founders of nongovernmental organizations and other nonprofit entities; entrepreneurs; government servants in federal, state, and local offices and the judiciary--just a few areas in which our alumni's talent and passion and dedication have made a difference. Among the School’s graduates are U.S. Presidents and Supreme Court Justices; and among its far-reaching projects, the Information Society Project and the China Center.

Career History
Chief Legal Officer
2019 - Current

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Executive Vice President & General Counsel
2011 - 2019

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Chief Tax Officer, Secretary & General Counsel
2008 - 2011

Bunge is a leading agribusiness and food company with integrated operations that circle the globe, stretching from the farm field to the retail shelf. We're working on one of the world's biggest challenges - how to ensure food security for a growing population in a sustainable way. Our over 35,000 employees contribute by helping farmers produce larger harvests, by ensuring a seamless connection between farmers and customers and among regions, and by producing high-quality products ranging from animal feed to consumer foods to renewable fuels. In approximately 40 countries you can find Bunge: originating oilseeds and grains from the world's primary growing regions and transporting them to customers worldwide; crushing oilseeds to make meal for the livestock industry and oil for the food processing, food service and biofuel industries; producing bottled oils, mayonnaise, margarines and other food products for consumers; crushing sugarcane to make sugar, ethanol and electricity; milling wheat and corn for food processors, bakeries, brewers and other commercial customers; and selling fertilizer to farmers

Boards & Committees
Member, Executive Committee
2018 - Current

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Director
2012 - Current

Celgene Ltd. develops human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialisation of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company is headquartered in Uxbridge, the United Kingdom.

Treasurer & Director
Current

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T. Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

Director
Current

JANJ’s mission is to inspire and prepare young people in grades K-12 to succeed in a global economy through real world relationships with business, government, and education partners that can help them develop the employability and financial literacy skills needed to succeed in the 21st century. Our innovative hands-on curriculum – provided at no cost to schools, students, or their families – emphasizes real world learning experiences, and motivates youth to achieve by connecting them with corporate and community role models committed to investing in their future. A well-known leader in the field of financial literacy, career readiness, and economic education, JANJ is recognized by the NJ Department of Education, NJ Business & Industry Association, NJ Department of Labor & Workforce Development, NJ State Employment and Training Commission, and the office of the Lieutenant Governor. During the 2014-2015 school year, JANJ reached 57,502 students statewide through a dedicated network of 4,000+ corporate and community volunteers. Established in 1953, JANJ is one of 115 affiliates of JA USA,whose reach extends to 4.6 million+ students nationwide and 10 million+ worldwide.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$2,500 - $4,999
2018

JANJ’s mission is to inspire and prepare young people in grades K-12 to succeed in a global economy through real world relationships with business, government, and education partners that can help them develop the employability and financial literacy skills needed to succeed in the 21st century. Our innovative hands-on curriculum – provided at no cost to schools, students, or their families – emphasizes real world learning experiences, and motivates youth to achieve by connecting them with corporate and community role models committed to investing in their future. A well-known leader in the field of financial literacy, career readiness, and economic education, JANJ is recognized by the NJ Department of Education, NJ Business & Industry Association, NJ Department of Labor & Workforce Development, NJ State Employment and Training Commission, and the office of the Lieutenant Governor. During the 2014-2015 school year, JANJ reached 57,502 students statewide through a dedicated network of 4,000+ corporate and community volunteers. Established in 1953, JANJ is one of 115 affiliates of JA USA,whose reach extends to 4.6 million+ students nationwide and 10 million+ worldwide.

$1,000 - $2,499
2017

JANJ’s mission is to inspire and prepare young people in grades K-12 to succeed in a global economy through real world relationships with business, government, and education partners that can help them develop the employability and financial literacy skills needed to succeed in the 21st century. Our innovative hands-on curriculum – provided at no cost to schools, students, or their families – emphasizes real world learning experiences, and motivates youth to achieve by connecting them with corporate and community role models committed to investing in their future. A well-known leader in the field of financial literacy, career readiness, and economic education, JANJ is recognized by the NJ Department of Education, NJ Business & Industry Association, NJ Department of Labor & Workforce Development, NJ State Employment and Training Commission, and the office of the Lieutenant Governor. During the 2014-2015 school year, JANJ reached 57,502 students statewide through a dedicated network of 4,000+ corporate and community volunteers. Established in 1953, JANJ is one of 115 affiliates of JA USA,whose reach extends to 4.6 million+ students nationwide and 10 million+ worldwide.

$1,000 - $2,499
2016

JANJ’s mission is to inspire and prepare young people in grades K-12 to succeed in a global economy through real world relationships with business, government, and education partners that can help them develop the employability and financial literacy skills needed to succeed in the 21st century. Our innovative hands-on curriculum – provided at no cost to schools, students, or their families – emphasizes real world learning experiences, and motivates youth to achieve by connecting them with corporate and community role models committed to investing in their future. A well-known leader in the field of financial literacy, career readiness, and economic education, JANJ is recognized by the NJ Department of Education, NJ Business & Industry Association, NJ Department of Labor & Workforce Development, NJ State Employment and Training Commission, and the office of the Lieutenant Governor. During the 2014-2015 school year, JANJ reached 57,502 students statewide through a dedicated network of 4,000+ corporate and community volunteers. Established in 1953, JANJ is one of 115 affiliates of JA USA,whose reach extends to 4.6 million+ students nationwide and 10 million+ worldwide.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jonathan Biller. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jonathan Biller's profile does not indicate a business or promotional relationship of any kind between RelSci and Jonathan Biller.